Concepedia

Blisse Vakkalagadda

BV

Statistics

Publications

12

Citations

522

H-Index

12

Active since

2008

Affiliations

Bristol-Myers Squibb (United States)(Current)

Pfizer (United States)

GlaxoSmithKline (United States)

Blisse Vakkalagadda is an author at Bristol-Myers Squibb (United States) specializing in pharmacology, pharmacokinetics, and clinical pharmacology.

ORCID

Publications per year

2008–2022

12

Publications

12

Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa

Blisse Vakkalagadda, Charles Frost, Wonkyung Byon et al. · American Journal of Cardiovascular Drugs · 2016 · 117 citations

, , +5

Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches

M. Fakes, Blisse Vakkalagadda, Feng Qian et al. · International Journal of Pharmaceutics · 2008 · 105 citations

, , +16

A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors.

Lillian L. Siu, K. Papadopoulos, Steven R. Alberts et al. · Journal of Clinical Oncology · 2010 · 62 citations

, , +14

Leveraging patient‐centric sampling for clinical drug development and decentralized clinical trials: Promise to reality

Katie F. Maass, Matthew Barfield, Mototsugu Ito et al. · Clinical and Translational Science · 2022 · 47 citations · Full text

, , +15

Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer

Dana E. Rathkopf, Glenn Liu, Michael A. Carducci et al. · Clinical Cancer Research · 2010 · 44 citations · Full text

, , +16

1–5 of 12